昌吉那家医院看阳痿昌吉割包皮 多久康复,昌吉割包皮得多少,昌吉早孕试纸一条明显一条不明显,昌吉如何正确治疗阳痿,昌吉女生人流,昌吉无痛打胎最好的医院,昌吉怎么割包皮

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

SAN FRANCISCO, Sept. 22 (Xinhua) -- Facebook on Thursday introduced Timeline, a new profile design featuring milestones of one's life on a single page.At Facebook's f8 developer conference, Chief Executive Officer Mark Zuckerberg promoted the new feature, a blog-like presentation that let users scrolls vertically through the big moments of one's life."It's how you can tell the whole story of your life in a single page," said Zuckerberg, showing his Timeline which started from a baby photo.Zuckerberg assured users that they have complete control over their Timeline, saying that they can decide what content will appear and who can see it. The new feature will be available in a few weeks.Half a billion people are using Facebook in the world everyday, according to Zuckerberg.

VIENNA, Aug. 11 (Xinhua) -- Austrian researchers have developed a method of using fungi and produced enzymes to split Polyethylene Terephthalate (PET) material into their initial state, enabling the recovery of all individual components, said the Austrian Center of Industrial Biotechnology (ACIB) Thursday in a press release.Enzyme is a special protein that acts as biological catalyst, for example, bacteria and fungi in the nature can break down long chain molecules.Researchers from the Technical University of Graz, the Technical University of Vienna and the Agricultural University of Vienna jointly found that efficient enzymes are capable to break and split PET into small fragments.With different methods, the researchers forced the fungi to overproduce their precious "split-tools" after they are modified and improved by genetic engineering.Through the new method developed by the ACIB, it is now possible to decompose the PET polymer to its initial monomers with high product quality and from this to produce new high-quality materials again.This circuit avoids waste and thus saves resources and is friendly to the environment, said Geog Guebitz, head of the Research Department on Enzymes and Polymers in the ACIB.He further explained that the ACIB has established a partnership with some industrial enterprises to carry out application experiments. From the current splitting time of 24 hours, the researchers expect to shorten the whole process to "a few hours," he added.PET is a common plastic material in the polyester family, widely used in the textile industry. PET film is mainly used in electrical insulation materials, which can be also used for production of film, X-ray films and computer taps, even to produce plastic bottle and other blow molding products.

PARIS, Aug. 7 (Xinhua) -- European heavy-lift launcher Ariane 5 lifted off two communication satellites on Saturday.The Ariane 5, carrying Astra 1N and BSAT-3c/JCSAT-110R, was launched at 2252 GMT on Saturday from Kourou launch centre in French Guiana, according to live broadcast of the launching process.This was the fourth mission of Ariane 5 in 2011 and its 203th flight that sent off the two satellites Saturday night to their respective geostationary transfer orbits.Astra 1N, to be separated first, is built by EADS Astrium in Toulouse, France, for the Luxembourg-based operator SES Astra. With a designed lifespan of 15 years, it has an estimated liftoff mass of 5,350 kg and is fitted with 52 active Ku-band transponders.It is initially to deliver interim capacity from an orbital position of 28.2 degree East, and will subsequently move to SES Astra's prime location at 19.2 degree East for primary and backup services.BSAT-3c/JCSAT-110R is manufactured by Lockheed Martin Commercial Space Systems in Newtown, Pennsylvania, for Japanese operators B-SAT Corporation and SKY Perfect JSAT Corporation. This satellite weighs approximately 2,910 kg at launch time. It is to be positioned at 110 degree East longitude in geostationary orbit with a lifetime exceeding 16 years.This Ariane 5 flight has been postponed twice, firstly due to some technical problem in early July and then delayed by bad weather.Arianespace plans to achieve six Ariane 5 missions through this year.